LUZZIO Michael Joseph,PAPILLON Julien,VISSER Michael Scott
申请号：
SI201530945
公开号：
SI3177608T1
申请日:
2015.08.05
申请国别(地区):
SI
年份:
2020
代理人:
摘要：
PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.
